Preparing for the introduction of new technologies: who is going to pay for them?
Marshall
Paul R
PR
Cordis, a Johnson & Johnson Co., USA.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000008:administration & dosage; D020811:Biomedical Technology; D001918:Brachytherapy / Q000191:economics* / Q000295:instrumentation; D002986:Clinical Trials as Topic; D003324:Coronary Artery Disease / Q000532:radiotherapy / Q000601:surgery; D023903:Coronary Restenosis / Q000532:radiotherapy; D006801:Humans; D007349:Insurance, Health, Reimbursement; D020123:Sirolimus / Q000008:administration & dosage; D015607:Stents / Q000009:adverse effects / Q000191:economics*; D013673:Technology Assessment, Biomedical / Q000191:economics*; D014481:United States
D000900:Anti-Bacterial Agents; D020123:Sirolimus